Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2000 Nov-Dec;10(6):395-403.
doi: 10.1002/1099-1654(200011/12)10:6<395::aid-rmv298>3.0.co;2-v.

Innate defences against viraemia

Affiliations
Review

Innate defences against viraemia

I P Singh et al. Rev Med Virol. 2000 Nov-Dec.

Abstract

Human blood plasma has been reported to possess nonspecific antiviral activity. This activity is due to several preexisting naturally occurring molecules that are either active against individual members or a family of viruses. These molecules, however, have not been adequately studied to reveal their molecular structures and mechanisms of action presumably because of their low and nonspecific antiviral action. Therefore, their possible role against viraemia remains unknown. Recently, two naturally occurring nonspecific broad-spectrum antiviral agents, University of Texas Inhibitor beta (UTIbeta) glycoprotein and high density lipoprotein, have been described in human serum. They are active against DNA and RNA viruses and one of them, UTIbeta, possesses significant antiviral activity of 40 units/mL. Since preexisting antiviral molecules in serum appear to be the only defence mechanisms available at the onset of viral infection they may have protective significance against viraemia. In view of this potential, we have undertaken to review the properties of these innate viral inhibitory molecules.

PubMed Disclaimer

Similar articles

  • Novel activities of safe-in-human broad-spectrum antiviral agents.
    Ianevski A, Zusinaite E, Kuivanen S, Strand M, Lysvand H, Teppor M, Kakkola L, Paavilainen H, Laajala M, Kallio-Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenych V, Bjørås M, Nordbø SA, Dumpis U, Vitkauskiene A, Öhrmalm C, Bondeson K, Bergqvist A, Aittokallio T, Cox RJ, Evander M, Hukkanen V, Marjomaki V, Julkunen I, Vapalahti O, Tenson T, Merits A, Kainov D. Ianevski A, et al. Antiviral Res. 2018 Jun;154:174-182. doi: 10.1016/j.antiviral.2018.04.016. Epub 2018 Apr 23. Antiviral Res. 2018. PMID: 29698664 Free PMC article. Review.
  • Antiviral activity of innate immune protein ISG15.
    Harty RN, Pitha PM, Okumura A. Harty RN, et al. J Innate Immun. 2009;1(5):397-404. doi: 10.1159/000226245. J Innate Immun. 2009. PMID: 19680460 Free PMC article. Review.
  • Curcumin as an Antiviral Agent.
    Jennings MR, Parks RJ. Jennings MR, et al. Viruses. 2020 Oct 31;12(11):1242. doi: 10.3390/v12111242. Viruses. 2020. PMID: 33142686 Free PMC article. Review.
  • Cationic host defence peptides: potential as antiviral therapeutics.
    Gwyer Findlay E, Currie SM, Davidson DJ. Gwyer Findlay E, et al. BioDrugs. 2013 Oct;27(5):479-93. doi: 10.1007/s40259-013-0039-0. BioDrugs. 2013. PMID: 23649937 Free PMC article. Review.
  • Lipoproteins account for part of the broad non-specific antiviral activity of human serum.
    Singh IP, Chopra AK, Coppenhaver DH, Ananatharamaiah GM, Baron S. Singh IP, et al. Antiviral Res. 1999 Jul;42(3):211-8. doi: 10.1016/s0166-3542(99)00032-7. Antiviral Res. 1999. PMID: 10443533

Cited by

References

    1. Smorodintsev AA. Basic mechanism of nonspecific resistance to viruses in animals and man. Adv Virus Res 1960; 7: 327–376.
    1. Ginsberg HS. Serum and tissue inhibitors of virus. Bacteriol Rev 1960; 24: 141–150. - PMC - PubMed
    1. Singh IP, Coppenhaver DH, Chopra AK, Baron S. Further characterization of a broad‐spectrum antiviral substance in human serum. Immunology 1992; 5: 293–303. - PubMed
    1. Singh IP, Chopra AK, Coppenhaver DH, Ananthramiah GM, Baron S. Lipoproteins account for part of the broad non‐specific antiviral activity of human serum. Antiviral Res 1999; 42: 211–218. - PubMed
    1. Gerna G, Cattaneo E, Cereda PM, Revelo MG, Achilli G. Human coronavirus OC43 serum inhibitor and neutralizing antibody by a new plaque‐reduction assay. Proc Soc Exp Biol Med 1980; 163: 360–366. - PubMed